(Q34164112)

31 July 2017

1 reference

title

The role of blood glucose-lowering drugs in the light of the UKPDS. United Kingdom Prospective Diabetes Study (English)

1 reference

31 July 2017

1 reference

L Monnier

1

1 reference

31 July 2017

1 September 1999

1 reference

Diabetes, Obesity and Metabolism

31 July 2017

1 reference

31 July 2017

1 Suppl 2

1 reference

31 July 2017

S14-23

1 reference

Long-term glycemic control relates to mortality in type II diabetes.

31 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Hyperglycemia and microvascular and macrovascular disease in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Bedtime dosing of glyburide and the treatment of type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Postprandial hyperglycaemia and alpha-glucosidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Drug therapy of postprandial hyperglycaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Oral antidiabetic agents. A guide to selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Stepwise and combination drug therapy for the treatment of NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Role of insulin resistance in the pathogenesis of NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Implications of blood glucose, insulin resistance and beta-cell function in impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Occurrence of low blood glucose concentrations during the afternoon in type 2 (non-insulin-dependent) diabetic patients on oral hypoglycaemic agents: importance of blood glucose monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

21 January 2018

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Antihyperglycaemic agents. Drug interactions of clinical importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S2014.X

10.1046/J.1463-1326.1999.0010S2014.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11221798